Codexis Total Liabilities 2010-2025 | CDXS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Codexis total liabilities from 2010 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Codexis total liabilities from 2010 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$225.3B
Amgen (AMGN)	$164.8B
Gilead Sciences (GILD)	$144.5B
Vertex Pharmaceuticals (VRTX)	$120.6B
Bristol Myers Squibb (BMY)	$98.6B
CSL (CSLLY)	$85.4B
GSK (GSK)	$77.7B
Regeneron Pharmaceuticals (REGN)	$60.8B
Alnylam Pharmaceuticals (ALNY)	$42.9B
Argenex SE (ARGX)	$36.2B
BioNTech SE (BNTX)	$27.7B
Royalty Pharma (RPRX)	$20.6B
Insmed (INSM)	$19.7B
Biogen (BIIB)	$19.3B
Illumina (ILMN)	$17.3B
Genmab (GMAB)	$15B
Genmab (GNMSF)	$15B
Incyte (INCY)	$13.6B
Moderna (MRNA)	$13.2B
Exelixis (EXEL)	$12.4B
QIAGEN (QGEN)	$11.5B
BioMarin Pharmaceutical (BMRN)	$11.3B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.2B
Bio-Techne Corp (TECH)	$9.2B
Exact Sciences (EXAS)	$9.1B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Legend Biotech (LEGN)	$8B
Roivant Sciences (ROIV)	$7.9B